Guardant Health (FRA:5GH) LT-Debt-to-Total-Asset : 0.77 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guardant Health LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Guardant Health's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.77.

Guardant Health's long-term debt to total assets ratio declined from Mar. 2023 (0.89) to Mar. 2024 (0.77). It may suggest that Guardant Health is progressively becoming less dependent on debt to grow their business.

Guardant Health LT-Debt-to-Total-Asset Historical Data

The historical data trend for Guardant Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health LT-Debt-to-Total-Asset Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.37

0.62

0.84

0.74

Guardant Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.89	0.73	0.74	0.74	0.77

Guardant Health LT-Debt-to-Total-Asset Calculation

Guardant Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	1215.771	/	1638.148
	=	0.74

Guardant Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	1213.957	/	1568.23
	=	0.77

Guardant Health (FRA:5GH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Guardant Health LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Guardant Health's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (FRA:5GH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (FRA:5GH) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

GH:USA

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health (FRA:5GH) Headlines

No Headlines